Gilead Experiencing Bumpy Ride Despite Strong Fundamentals

Gilead Experiencing Bumpy Ride Despite Strong Fundamentals In December 2013, Gilead launched Sovaldi, a medicine to treat hepatitis C, and its sales boosted revenues for the calendar year 2014 which were around $ 10.3 billion. In October 2014, the company … Continue reading